Our portfolio / Children’s Health / Rare Disease
Regatta Bio
Next-generation Treg cell therapies.
Regatta Bio develops regulatory T cell (Treg) therapies for chronic Graft-versus-Host Disease, solid organ rejection, and autoimmune disorders. Its work aims to address persistent challenges in immune health.
Visit Regatta Bio
Children’s health innovation
A 2026 CIF Innovation Prize recipient.
CIF recognized Regatta Bio at the Children’s Health Innovation Prize & Summit with a $100,000 equity investment prize.
Explore the Children’s Health / Rare Disease program